Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04919811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Study acronym: TRUST-II
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 77 sitesv13
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 224 to confirmed 217 · Study sites: 73 to 77 · Primary completion date changed from estimate of Jun 2025 to Jun 11, 2025 · 4 morev12 Show 7 more changesShow less
    • Enrollment target: estimated 224 to confirmed 217
    • Study sites: 73 to 77
    • Primary completion date changed from estimate of Jun 2025 to Jun 11, 2025
    • Completion date: Jun 2027 to Dec 2027
    • Eligibility criteria expanded, about 716 words
    • Study description shortened, about 36 words
    • Collaborators shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  3. Lead sponsor: AnHeart Therapeutics Inc. to Nuvation Bio Inc. Site details revised at 2 of 73 sites · Collaborators expanded, about 3 wordsv11 Show 2 more changesShow less
    • Site details revised at 2 of 73 sites
    • Collaborators expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  4. Enrollment target: 154 to 224 Study sites: 72 to 73 · Eligibility criteria shortened, about 14 words · Study description expanded, about 33 wordsv10 Show 3 more changesShow less
    • Study sites: 72 to 73
    • Eligibility criteria shortened, about 14 words
    • Study description expanded, about 33 words

    See this version in full on ClinicalTrials.gov ↗

  5. Site details revised at 6 of 72 sitesv9
Show 7 earlier versionsHide 7 earlier versions
  1. Enrollment target: 119 to 154 Study sites: 59 to 72 · Eligibility criteria expanded, about 138 words · Study description expanded, about 1 wordv8 Show 3 more changesShow less
    • Study sites: 59 to 72
    • Eligibility criteria expanded, about 138 words
    • Study description expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  2. Site details revised at 9 of 59 sitesv7
  3. Study sites: 38 to 59v6
  4. Study sites: 28 to 38v5
  5. Study sites: 17 to 28v4
  6. Study sites: 3 to 17v3
  7. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 2021 to Sep 1, 2021 · Secondary endpoints revised (4) · Study title shortened, about 1 wordv2 Show 3 more changesShow less
    • Start date changed from estimate of Jun 2021 to Sep 1, 2021
    • Secondary endpoints revised (4)
    • Study title shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Trial Details
NCT Number NCT04919811
Lead Sponsor Nuvation Bio Inc.
Conditions Non Small Cell Lung Cancer
Enrollment 217 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov